You are here

Home › CureVac says COVID vaccine produced immune response in early-stage trial › CureVac says COVID vaccine produced immune response in early-stage trial

CureVac says COVID vaccine produced immune response in early-stage trial

Primary tabs

CureVac says COVID vaccine produced immune response in early-stage trial

Fri, 2023-01-06 09:19 — mike kraft
CureVac says COVID vaccine produced immune response in early-stage trial Germany's CureVac AG said on Friday its second-generation COVID-19 vaccine produced virus-neutralizing antibodies against the BA.1 subvariant of Omicron, based on preliminary data from an early-stage trial. Reuters Reuters

...

The company said the vaccine was shown to be generally well tolerated in the trial. Younger adults showed the presence of neutralizing antibodies beginning at the lowest tested dose, data showed.

...

Country / Region Tags: 
Germany
Global
General Topic Tags: 
COVID-19
Treatments
Disease
Disease Prevention
Health
Mutations
Pandemics
Research
Vaccinations
Problem, Solution, SitRep, or ?: 
Situation Report
Groups this Group Post belongs to: 
Global Health
Medical - global
Vaccines
- Private group -
Workflow history
Revision ID Field name Date Old state New state name By Comment Operations
No state No state
howdy folks